Research graph
References from In silico miniaturization of the necitumumab EGFR-binding interface into a peptide scaffold for targeted therapy of EGFR-overexpressing NSCLC. Local targets link to admitted publications; unresolved targets remain external evidence.
The global burden of lung Cancer: current status and future trends
10.1038/s41571-023-00798-3 · 2023 · External reference
Lung Cancer
10.1016/s0140-6736(21)00312-3 · 2021 · External reference
A review on non-small cell lung Cancer
10.1016/j.vacun.2023.12.003 · 2024 · External reference
Acute and late toxicities of concurrent chemoradiotherapy for locally-advanced non-small cell lung cancer
10.3390/cancers9090120 · 2017 · External reference
Radiation therapy-associated toxicity: Etiology, management, and prevention
2021 · External reference
New light on chemotherapy toxicity and its prevention
10.1038/s44276-024-00064-8 · 2024 · External reference
The incidence and severity of patient-reported side effects of chemotherapy in routine clinical care: a prospective observational study
2023 · External reference
Epidermal growth factor receptor mutations in lung Cancer
10.1038/nrc2088 · 2007 · External reference
Synthesis and anticancer properties of novel Dolastatin 10 Analogs featuring five-membered heterocyclic rings with a linkable group at the C-terminus
10.1016/j.bmc.2024.117794 · 2024 · External reference
The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
10.2147/cmar.s186042 · 2019 · External reference
Portrazza (Necitumumab), an IgG1 monoclonal antibody, FDA approved for advanced squamous non–small-cell lung cancer
2016 · External reference
10.2147/ott.s114039
10.2147/ott.s114039 · External reference
Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance
10.1158/1535-7163.mct-17-0575 · 2018 · External reference
Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
10.1016/j.apsb.2022.07.020 · 2023 · External reference
Peptide-drug conjugates as next-generation therapeutics: exploring the potential and clinical progress
10.3390/bioengineering12050481 · 2025 · External reference
Recent innovations in peptide based targeted drug delivery to cancer cells
10.3390/biomedicines4020011 · 2016 · External reference
Antibody–drug conjugates (ADCs): a review of structural design, technological evolution, and future perspectives
10.3390/molecules31071180 · 2026 · External reference
Peptide-drug conjugates: a new hope for cancer
10.1002/psc.70040 · 2025 · External reference
Peptide-drug conjugates: a new paradigm for targeted Cancer therapy
10.1016/j.ejmech.2023.116119 · 2024 · External reference
Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer
10.1056/nejmoa2107322 · 2021 · External reference
177Lu-DOTATATE for the treatment of Gastroenteropancreatic neuroendocrine Tumors
10.1080/17474124.2019.1685381 · 2019 · External reference
Phage display
10.1021/cr960065d · 1997 · External reference
Novel cyclic peptides for targeting EGFR and EGRvIII mutation for drug delivery
10.3390/pharmaceutics14071505 · 2022 · External reference
10.1073/pnas.94.23.12297
10.1073/pnas.94.23.12297 · External reference
Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid
10.1073/pnas.81.13.3998 · 1984 · External reference
10.3390/ijms25031798
10.3390/ijms25031798 · External reference
High throughput virtual screening (HTVS) of peptide library: technological advancement in ligand discovery
10.1016/j.ejmech.2022.114766 · 2022 · External reference
Advances in computer-aided drug design: from molecular docking to artificial intelligence-driven therapeutic discovery
10.1016/j.aspetd.2026.100024 · 2026 · External reference
An in silico approach to design peptide mimetics based on docking and molecular dynamics simulation of EGFR–Matuzumab complex
10.1007/s13738-016-0898-7 · 2016 · External reference
A rational approach for creating peptides mimicking antibody binding
10.1038/s41598-018-37201-6 · 2019 · External reference
EGFR-targeted and MMP-activated membranolytic peptides kill Cancer cells specifically in vitro and reduce tumor growth in vivo
10.1021/acs.molpharmaceut.5c01774 · 2026 · External reference
EGFR-binding peptides: from computational design towards tumor-targeting of adeno-associated virus capsids
10.3390/ijms21249535 · 2020 · External reference
The afatinib resistance of in vivo generated H1975 lung Cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival Signaling
10.18632/oncotarget.7746 · 2016 · External reference
EGFR in cancer: signaling mechanisms, drugs, and acquired resistance
10.3390/cancers13112748 · 2021 · External reference
Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: current developments in medicinal chemistry
10.1002/med.21488 · 2018 · External reference
Targeting EGFR T790M mutation in NSCLC: from biology to evaluation and treatment
10.1016/j.phrs.2017.01.003 · 2017 · External reference
Peptide–drug conjugates bearing an antimitotic Ahx-DA1 payload achieve potent antitumor activity in Her2-amplified and EGFR-positive KRAS-mutant cancers in vivo
10.1016/j.bmc.2026.118674 · 2026 · External reference
Unresolved reference
External reference
Applying unbiased, functional criteria allows selection of novel cyclic peptides for effective targeted drug delivery to malignant prostate cancer cells
10.3390/pharmaceutics17070866 · 2025 · External reference
Cell-penetrating peptides selectively cross the blood-brain barrier in vivo
10.1371/journal.pone.0139652 · 2015 · External reference
Site-specific stabilization of Minigastrin Analogs against enzymatic degradation for enhanced Cholecystokinin-2 receptor targeting
10.7150/thno.24378 · 2018 · External reference
HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib
10.3892/ol.2016.5373 · 2016 · External reference
A fluorogenic probe for predicting treatment response in non-small cell lung Cancer with EGFR-activating mutations
10.1038/s41467-022-34627-5 · 2022 · External reference
Epidermal growth factor receptor expression affects proliferation and apoptosis in non-small cell lung Cancer cells via the extracellular signal-regulated kinase/microRNA 200a Signaling pathway
2018 · External reference
EGFR-mediated expression of Aquaporin-3 is involved in human skin fibroblast migration
10.1042/bj20060816 · 2006 · External reference
Novel cyclic peptide–drug conjugate P6-SN38 toward targeted treatment of EGFR overexpressed non-small cell lung cancer
10.3390/pharmaceutics16121613 · 2024 · External reference
10.1016/j.jconrel.2026.114993
10.1016/j.jconrel.2026.114993 · External reference
Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal Cancer: a systematic review
2018 · External reference
Mechanisms of cutaneous toxicities to EGFR inhibitors
10.1038/nrc1970 · 2006 · External reference
Unresolved reference
External reference
10.33140/oajast.04.02.06
10.33140/oajast.04.02.06 · External reference
OPLS4: improving force field accuracy on challenging regimes of chemical space
10.1021/acs.jctc.1c00302 · 2021 · External reference
Nosé–Hoover chains: the canonical ensemble via continuous dynamics
10.1063/1.463940 · 1992 · External reference
Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring
10.1021/jm060522a · 2006 · External reference
The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling
10.1002/prot.23106 · 2011 · External reference
Unresolved reference
2026 · External reference
Unresolved reference
2026 · External reference
